Premium
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
Author(s) -
Hampel Harald,
Shaw Leslie M.,
Aisen Paul,
Chen Christopher,
Lleó Alberto,
Iwatsubo Takeshi,
Iwata Atsushi,
Yamada Masahito,
Ikeuchi Takeshi,
Jia Jianping,
Wang Huali,
Teunissen Charlotte E.,
Peskind Elaine,
Blennow Kaj,
Cummings Jeffrey,
Vergallo Andrea
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12372
Subject(s) - lumbar puncture , disease , medicine , intensive care medicine , biomarker , adverse effect , clinical practice , lumbar , cerebrospinal fluid , physical therapy , pathology , surgery , biochemistry , chemistry
Recent advances in developing disease‐modifying therapies (DMT) for Alzheimer's disease (AD), and the recognition that AD pathophysiology emerges decades before clinical symptoms, necessitate a paradigm shift of health‐care systems toward biomarker‐guided early detection, diagnosis, and therapeutic decision‐making. Appropriate incorporation of cerebrospinal fluid biomarker analysis in clinical practice is an essential step toward system readiness for accommodating the demand of AD diagnosis and proper use of DMTs—once they become available. However, the use of lumbar puncture (LP) in individuals with suspected neurodegenerative diseases such as AD is inconsistent, and the perception of its utility and safety differs considerably among medical specialties as well as among regions and countries. This review describes the state‐of‐the‐art evidence concerning the safety profile of LP in older adults, discusses the risk factors for LP‐associated adverse events, and provides recommendations and an outlook for optimized use and global implementation of LP in individuals with suspected AD.